2015 Meeting Archives

Presentation Slides - February 26, 2015

Stop TB Meeting

Update on global TB epidemiology
(for presentation slides, please email ferguson-king@bclung.ca)
Dr. Mario Raviglione, World Health Organization, Geneva, Switzerland

Global MDR-TB Update
Dr. Paul Nunn, London, UK

MDR-TB: Linking Diagnosis and Treatment
Dr. Charles Daley, National Jewish Medical and Research Center, Denver, CO, USA

Programmatic technical assistance in high burden DR - TB settings
Dr. Lisa Chen, Curry International TB Center, San Francisco, CA, USA

Shortened MDR - TB Regimen
Dr. ID Rusen, The Union, Paris, France (IUATLD)

Multidrug-resistent TB among immigrants and refugees to the US
Dr. Sasi Jonnalagadda, Centers for Diease Control and Prevention, Atlanta, GA, USA

Nursing-Sponsored Session

Role of social determinants of health on TB among Inuit in Canada
Ms. Anna Claire Ryan, Inuit Tapiriit Kanatami, Ottawa, ON, Canada

TAIMA TB - Community-driven studies for TB prevention and control in Nunavut 
(for presentation slides, please email ferguson-king@bclung.ca)
Dr. Gonzalo Alvarez, University of Ottawa, ON, Canada

Tipping points in the TB experience of Aboriginal Peoples of the Canadian Prairies
Dr. Maria Maya, University of Alberta, Edmonton, AB, Canada

TB program and smoking cessation campaign
Dr. Amy Sullivan, Multnomah County Health Department, Portland, OR, USA

Housing-related determinants of TB infection and disease in Nunavik, Quebec
Dr. Faiz Ahmad Khan, McGill International TB Centre, Montreal QC, Canada

Keynote Speakers

The Beyond TB Lecture: Migrants in need: Evolving patterns, ongoing challenges
Prof. Catherine Dauvergne, University of British Columbia Law, Vancouver, BC, Canada

The George Comstock Lecture: Why can't we eliminate tuberculosis?
Dr. Neil Schluger, Columbia University Medical Center, New York, NY, USA

Presentation Slides - February 27, 2015

Re-Examining TB Control Policies and Controversies

Health care worker screening for LTBI in North America
Dr. Susan Dorman, Johns Hopkins University, Baltimore, MD, USA

Value of TB screening among foreign born persons
Dr. Pennan Barry, USA California Department of Public Health, Richmond, CA, USA

Isolation and quarantine: Evolving evidence and practice - US public health perspective
Dr. Gisela Schecter, UCSF and California Department of Public Health, Richmond, CA, USA

Developing a surveillance definition for binational TB cases
Ms. Rachel Yelk-Woodruff, Centers for Disease Control and Prevention, Atlanta, GA, USA

TB in Special Populations

The Public Health impact of TB in the correctional system
Ms. Sarah Bur, Federal Bureau of Prisons, Washington, DC, USA

Women and TB: Impact of gender
Dr. Jane Carter, Brown University, Providence, RI, USA

Challenges in management: Solid organ transplantation and TB
Dr. Michele I. Morris, University of Miami Miller School of Medicine, Miami, FL, USA

Risk of adverse infant outcomes associated with maternal TB in a low burden setting
Dr. Sylvia LaCourse, University of Washington, Seattle, WA, USA

Presentation Slides - February 28, 2015

TB and Diabetes

Roadblocks on the path to TB and DM implementation in New Mexico
Ms. Diana Fortune, New Mexico Department of Health, Santa Fe, NM, USA

Implementing TB-DM for your TB program
(for presentation slides, please email ferguson-king@bclung.ca)
Dr. Richard Brostrom, Department of Health, Honolulu, HI, USA

Refugees with Diabetes Mellitus have higher prevalence of latent TB infection
Dr. Matthew Magee, Georgia State University School of Public Health, Atlanta, GA, USA

TB Pharmacology

Therapeutic drug monitering for TB
Dr. Scott Heysell, University of Virginia School of Medicine, Charlottesville, VA, USA

Therapeutic drug monitering for improving TB treatment outcomes
Dr. Randall Reves, Denver Department of Health, Denver, CO, USA

Pharmacokinetics and doses of anti-TB drugs in children
Prof. Simon Schaaf, Stellenbosch University, Faculty of Medicine, Cape Town, SA

Clinical trials: Optimal use of new and existing medications
Dr. William J. Burman, Denver Health Hospital, Denver, CO, USA

DM2 is associatied with severe adverse effects in drug resistent TB
Dr. Marcela Veronica Muñoz-Torrico, National Institute of Respiratory Diseases, Mexico City, Distrito Federal, Mexico

Page Last Updated: 23/06/2020